Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18 entries
Sorted by: Best Match Show Resources per page
Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW, Gray R.
PMID: 19996222
Clin Cancer Res. 2009 Dec 15;15(24):7693-7700. doi: 10.1158/1078-0432.CCR-09-1450.

PURPOSE: To perform an exploratory analysis of the relationship between gene expression and recurrence in operable hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-normal breast cancer patients treated with adjuvant doxorubicin-containing chemotherapy. EXPERIMENTAL DESIGN: RNA was extracted...

Cite
Sparano JA, Goldstein LJ, Childs BH, et al. Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res. 2009;15(24):7693-7700doi: 10.1158/1078-0432.CCR-09-1450.
Sparano, J. A., Goldstein, L. J., Childs, B. H., Shak, S., Brassard, D., Badve, S., Baehner, F. L., Bugarini, R., Rowley, S., Perez, E., Shulman, L. N., Martino, S., Davidson, N. E., Sledge, G. W., & Gray, R. (2009). Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 15(24), 7693-7700. https://doi.org/10.1158/1078-0432.CCR-09-1450
Sparano, Joseph A, et al. "Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 15,24 (2009): 7693-7700. doi: https://doi.org/10.1158/1078-0432.CCR-09-1450
Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW, Gray R. Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res. 2009 Dec 15;15(24):7693-7700. doi: 10.1158/1078-0432.CCR-09-1450. PMID: 19996222; PMCID: PMC3396025.
Copy Download .nbib Format: NLM
Urbanism, Neighborhood Context, and Social Networks.

City & society (Washington, D.C.)

Cornwell EY, Behler RL.
PMID: 28819338
City Soc (Wash). 2015 Sep;14(3):311-335. doi: 10.1111/cico.12124. Epub 2015 Sep 18.

Theories of urbanism suggest that the urban context erodes individuals' strong social ties with friends and family. Recent research has narrowed focus to the neighborhood context, emphasizing how localized structural disadvantage affects community-level cohesion and social capital. In this...

Cite
Cornwell EY, Behler RL. Urbanism, Neighborhood Context, and Social Networks. City Soc (Wash). 2015;14(3):311-335doi: 10.1111/cico.12124.
Cornwell, E. Y., & Behler, R. L. (2015). Urbanism, Neighborhood Context, and Social Networks. City & society (Washington, D.C.), 14(3), 311-335. https://doi.org/10.1111/cico.12124
Cornwell, Erin York, and Behler, Rachel L. "Urbanism, Neighborhood Context, and Social Networks." City & society (Washington, D.C.) vol. 14,3 (2015): 311-335. doi: https://doi.org/10.1111/cico.12124
Cornwell EY, Behler RL. Urbanism, Neighborhood Context, and Social Networks. City Soc (Wash). 2015 Sep;14(3):311-335. doi: 10.1111/cico.12124. Epub 2015 Sep 18. PMID: 28819338; PMCID: PMC5557022.
Copy Download .nbib Format: NLM
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.

NPJ breast cancer

Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, Cronin K, Baehner FL, Cress R, Deapen D, Glaser SL, Hernandez BY, Lynch CF, Mueller L, Schwartz AG, Schwartz SM, Stroup A, Sweeney C, Tucker TC, Ward KC, Wiggins C, Wu XC, Penberthy L, Shak S.
PMID: 28721379
NPJ Breast Cancer. 2016 Jun 08;2:16017. doi: 10.1038/npjbcancer.2016.17. eCollection 2016.

The 21-gene Recurrence Score assay is validated to predict recurrence risk and chemotherapy benefit in hormone-receptor-positive (HR+) invasive breast cancer. To determine prospective breast-cancer-specific mortality (BCSM) outcomes by baseline Recurrence Score results and clinical covariates, the National Cancer Institute...

Cite
Petkov VI, Miller DP, Howlader N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2016;2:16017doi: 10.1038/npjbcancer.2016.17.
Petkov, V. I., Miller, D. P., Howlader, N., Gliner, N., Howe, W., Schussler, N., Cronin, K., Baehner, F. L., Cress, R., Deapen, D., Glaser, S. L., Hernandez, B. Y., Lynch, C. F., Mueller, L., Schwartz, A. G., Schwartz, S. M., Stroup, A., Sweeney, C., Tucker, T. C., Ward, K. C., Wiggins, C., Wu, X. C., Penberthy, L., & Shak, S. (2016). Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ breast cancer, 216017. https://doi.org/10.1038/npjbcancer.2016.17
Petkov, Valentina I, et al. "Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study." NPJ breast cancer vol. 2 (2016): 16017. doi: https://doi.org/10.1038/npjbcancer.2016.17
Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, Cronin K, Baehner FL, Cress R, Deapen D, Glaser SL, Hernandez BY, Lynch CF, Mueller L, Schwartz AG, Schwartz SM, Stroup A, Sweeney C, Tucker TC, Ward KC, Wiggins C, Wu XC, Penberthy L, Shak S. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2016 Jun 08;2:16017. doi: 10.1038/npjbcancer.2016.17. eCollection 2016. PMID: 28721379; PMCID: PMC5515329.
Copy Download .nbib Format: NLM
Erratum: Author Correction: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.

NPJ breast cancer

Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, Cronin K, Baehner FL, Cress R, Deapen D, Glaser SL, Hernandez BY, Lynch CF, Mueller L, Schwartz AG, Schwartz SM, Stroup A, Sweeney C, Tucker TC, Ward KC, Wiggins C, Wu XC, Penberthy L, Shak S.
PMID: 30003141
NPJ Breast Cancer. 2018 Jul 06;4:17. doi: 10.1038/s41523-018-0069-3. eCollection 2018.

[This corrects the article DOI: 10.1038/npjbcancer.2016.17.].

Cite
Petkov VI, Miller DP, Howlader N, et al. Erratum: Author Correction: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2018;4:17doi: 10.1038/s41523-018-0069-3.
Petkov, V. I., Miller, D. P., Howlader, N., Gliner, N., Howe, W., Schussler, N., Cronin, K., Baehner, F. L., Cress, R., Deapen, D., Glaser, S. L., Hernandez, B. Y., Lynch, C. F., Mueller, L., Schwartz, A. G., Schwartz, S. M., Stroup, A., Sweeney, C., Tucker, T. C., Ward, K. C., Wiggins, C., Wu, X. C., Penberthy, L., & Shak, S. (2018). Erratum: Author Correction: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ breast cancer, 417. https://doi.org/10.1038/s41523-018-0069-3
Petkov, Valentina I, et al. "Erratum: Author Correction: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study." NPJ breast cancer vol. 4 (2018): 17. doi: https://doi.org/10.1038/s41523-018-0069-3
Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, Cronin K, Baehner FL, Cress R, Deapen D, Glaser SL, Hernandez BY, Lynch CF, Mueller L, Schwartz AG, Schwartz SM, Stroup A, Sweeney C, Tucker TC, Ward KC, Wiggins C, Wu XC, Penberthy L, Shak S. Erratum: Author Correction: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2018 Jul 06;4:17. doi: 10.1038/s41523-018-0069-3. eCollection 2018. PMID: 30003141; PMCID: PMC6035253.
Copy Download .nbib Format: NLM
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer.

Therapeutic advances in medical oncology

Nitz U, Gluz O, Kreipe HH, Christgen M, Kuemmel S, Baehner FL, Shak S, Aktas B, Braun M, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Nuding B, Darsow M, Schumacher C, Krauss K, Malter W, Thill M, Warm M, Wuerstlein R, Kates RE, Harbeck N.
PMID: 33281950
Ther Adv Med Oncol. 2020 Nov 23;12:1758835920973130. doi: 10.1177/1758835920973130. eCollection 2020.

BACKGROUND: Endocrine sensitivity, as determined by response of the proliferation marker Ki-67 to short-term preoperative endocrine therapy (ET), is currently not included in adjuvant treatment decisions in hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- breast cancer (BC).METHODS:...

Cite
Nitz U, Gluz O, Kreipe HH, et al. The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. Ther Adv Med Oncol. 2020;12:1758835920973130doi: 10.1177/1758835920973130.
Nitz, U., Gluz, O., Kreipe, H. H., Christgen, M., Kuemmel, S., Baehner, F. L., Shak, S., Aktas, B., Braun, M., Lüdtke-Heckenkamp, K., Forstbauer, H., Grischke, E. M., Nuding, B., Darsow, M., Schumacher, C., Krauss, K., Malter, W., Thill, M., Warm, M., Wuerstlein, R., Kates, R. E., & Harbeck, N. (2020). The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. Therapeutic advances in medical oncology, 121758835920973130. https://doi.org/10.1177/1758835920973130
Nitz, Ulrike, et al. "The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer." Therapeutic advances in medical oncology vol. 12 (2020): 1758835920973130. doi: https://doi.org/10.1177/1758835920973130
Nitz U, Gluz O, Kreipe HH, Christgen M, Kuemmel S, Baehner FL, Shak S, Aktas B, Braun M, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Nuding B, Darsow M, Schumacher C, Krauss K, Malter W, Thill M, Warm M, Wuerstlein R, Kates RE, Harbeck N. The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. Ther Adv Med Oncol. 2020 Nov 23;12:1758835920973130. doi: 10.1177/1758835920973130. eCollection 2020. PMID: 33281950; PMCID: PMC7692353.
Copy Download .nbib Format: NLM
Reply to C. Shah et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE.
PMID: 27001578
J Clin Oncol. 2016 May 20;34(15):1824-5. doi: 10.1200/JCO.2016.66.4714. Epub 2016 Mar 21.

No abstract available.

Cite
Solin LJ, Gray R, Hughes LL, et al. Reply to C. Shah et al. J Clin Oncol. 2016;34(15):1824-5doi: 10.1200/JCO.2016.66.4714.
Solin, L. J., Gray, R., Hughes, L. L., Wood, W. C., Lowen, M. A., Badve, S. S., Baehner, F. L., Ingle, J. N., Perez, E. A., Recht, A., Sparano, J. A., & Davidson, N. E. (2016). Reply to C. Shah et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34(15), 1824-5. https://doi.org/10.1200/JCO.2016.66.4714
Solin, Lawrence J, et al. "Reply to C. Shah et al." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 34,15 (2016): 1824-5. doi: https://doi.org/10.1200/JCO.2016.66.4714
Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE. Reply to C. Shah et al. J Clin Oncol. 2016 May 20;34(15):1824-5. doi: 10.1200/JCO.2016.66.4714. Epub 2016 Mar 21. PMID: 27001578.
Copy Download .nbib Format: NLM
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.

NPJ breast cancer

Geyer CE, Tang G, Mamounas EP, Rastogi P, Paik S, Shak S, Baehner FL, Crager M, Wickerham DL, Costantino JP, Wolmark N.
PMID: 30456299
NPJ Breast Cancer. 2018 Nov 14;4:37. doi: 10.1038/s41523-018-0090-6. eCollection 2018.

The NSABP B-20 prospective-retrospective study of the 21-gene Oncotype DX Breast Cancer Recurrence Score® test predicted benefit from addition of chemotherapy to tamoxifen in node-negative, estrogen-receptor positive breast cancer when recurrence score (RS) was ≥31. HER2 is a component...

Cite
Geyer CE, Tang G, Mamounas EP, et al. 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ Breast Cancer. 2018;4:37doi: 10.1038/s41523-018-0090-6.
Geyer, C. E., Tang, G., Mamounas, E. P., Rastogi, P., Paik, S., Shak, S., Baehner, F. L., Crager, M., Wickerham, D. L., Costantino, J. P., & Wolmark, N. (2018). 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ breast cancer, 437. https://doi.org/10.1038/s41523-018-0090-6
Geyer, Charles E, et al. "21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer." NPJ breast cancer vol. 4 (2018): 37. doi: https://doi.org/10.1038/s41523-018-0090-6
Geyer CE, Tang G, Mamounas EP, Rastogi P, Paik S, Shak S, Baehner FL, Crager M, Wickerham DL, Costantino JP, Wolmark N. 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ Breast Cancer. 2018 Nov 14;4:37. doi: 10.1038/s41523-018-0090-6. eCollection 2018. PMID: 30456299; PMCID: PMC6235896.
Copy Download .nbib Format: NLM
Pediatric emergence delirium is linked to increased early postoperative negative behavior within two weeks after adenoidectomy: an observational study.

Brazilian journal of anesthesiology (Elsevier)

Houben A, Ghamari S, Fischer A, Neumann C, Baehner T, Ellerkmann RK.
PMID: 33887334
Braz J Anesthesiol. 2021 Apr 19; doi: 10.1016/j.bjane.2021.03.008. Epub 2021 Apr 19.

BACKGROUND: The aim of this prospective multicenter observational study was to measure the incidence of postoperative pediatric emergence delirium and to investigate the occurrence of early postoperative negative behavior within two weeks after outpatient adenoidectomy in preschool children.METHODS: The...

Cite
Houben A, Ghamari S, Fischer A, et al. Pediatric emergence delirium is linked to increased early postoperative negative behavior within two weeks after adenoidectomy: an observational study. Braz J Anesthesiol. 2021;doi: 10.1016/j.bjane.2021.03.008.
Houben, A., Ghamari, S., Fischer, A., Neumann, C., Baehner, T., & Ellerkmann, R. K. (2021). Pediatric emergence delirium is linked to increased early postoperative negative behavior within two weeks after adenoidectomy: an observational study. Brazilian journal of anesthesiology (Elsevier), . https://doi.org/10.1016/j.bjane.2021.03.008
Houben, Anne, et al. "Pediatric emergence delirium is linked to increased early postoperative negative behavior within two weeks after adenoidectomy: an observational study." Brazilian journal of anesthesiology (Elsevier) vol. (2021). doi: https://doi.org/10.1016/j.bjane.2021.03.008
Houben A, Ghamari S, Fischer A, Neumann C, Baehner T, Ellerkmann RK. Pediatric emergence delirium is linked to increased early postoperative negative behavior within two weeks after adenoidectomy: an observational study. Braz J Anesthesiol. 2021 Apr 19; doi: 10.1016/j.bjane.2021.03.008. Epub 2021 Apr 19. PMID: 33887334.
Copy Download .nbib Format: NLM
A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay.

Advances in radiation oncology

Lei RY, Carter DL, Antell AG, Nowels MA, Tole SP, Bennett JP, Turner M, Baehner FL, Leonard CE.
PMID: 33912731
Adv Radiat Oncol. 2020 Nov 01;6(2):100607. doi: 10.1016/j.adro.2020.10.020. eCollection 2021.

PURPOSE: To compare ipsilateral breast event (IBE) risks in patients with ductal carcinoma in situ of the breast (DCIS) post-lumpectomy, as estimated by breast radiation oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center (MSKCC) DCIS...

Cite
Lei RY, Carter DL, Antell AG, et al. A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay. Adv Radiat Oncol. 2020;6(2):100607doi: 10.1016/j.adro.2020.10.020.
Lei, R. Y., Carter, D. L., Antell, A. G., Nowels, M. A., Tole, S. P., Bennett, J. P., Turner, M., Baehner, F. L., & Leonard, C. E. (2021). A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay. Advances in radiation oncology, 6(2), 100607. https://doi.org/10.1016/j.adro.2020.10.020
Lei, Rachel Y, et al. "A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay." Advances in radiation oncology vol. 6,2 (2021): 100607. doi: https://doi.org/10.1016/j.adro.2020.10.020
Lei RY, Carter DL, Antell AG, Nowels MA, Tole SP, Bennett JP, Turner M, Baehner FL, Leonard CE. A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay. Adv Radiat Oncol. 2020 Nov 01;6(2):100607. doi: 10.1016/j.adro.2020.10.020. eCollection 2021. PMID: 33912731; PMCID: PMC8071725.
Copy Download .nbib Format: NLM
Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test.

Journal of surgical oncology

Jakubowski DM, Bailey H, Abran J, Blacklock A, Ciau N, Mies C, Tan V, Young R, Lau A, Baehner FL.
PMID: 32497318
J Surg Oncol. 2020 Jun 04; doi: 10.1002/jso.26050. Epub 2020 Jun 04.

BACKGROUND AND OBJECTIVE: Recent COVID-19 pandemic guidelines recommend genomic assessment of core biopsies to help guide treatment decisions in estrogen receptor (ER)-positive early-stage breast cancer. Herein we characterize biopsy and excisional breast cancer specimens submitted for 21-gene testing.METHODS: US...

Cite
Jakubowski DM, Bailey H, Abran J, et al. Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test. J Surg Oncol. 2020;doi: 10.1002/jso.26050.
Jakubowski, D. M., Bailey, H., Abran, J., Blacklock, A., Ciau, N., Mies, C., Tan, V., Young, R., Lau, A., & Baehner, F. L. (2020). Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test. Journal of surgical oncology, . https://doi.org/10.1002/jso.26050
Jakubowski, Debbie M, et al. "Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test." Journal of surgical oncology vol. (2020). doi: https://doi.org/10.1002/jso.26050
Jakubowski DM, Bailey H, Abran J, Blacklock A, Ciau N, Mies C, Tan V, Young R, Lau A, Baehner FL. Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test. J Surg Oncol. 2020 Jun 04; doi: 10.1002/jso.26050. Epub 2020 Jun 04. PMID: 32497318; PMCID: PMC7496790.
Copy Download .nbib Format: NLM
Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy.

Urologic oncology

Brooks MA, Thomas L, Magi-Galluzzi C, Li J, Crager MR, Lu R, Baehner FL, Abran J, Aboushwareb T, Klein EA.
PMID: 34824014
Urol Oncol. 2021 Nov 22; doi: 10.1016/j.urolonc.2021.10.005. Epub 2021 Nov 22.

PURPOSE: To assess the association of adverse pathology (AP), defined as high-grade (≥ Gleason Grade Group 3) and/or non-organ confined disease, with long-term oncologic outcomes after radical prostatectomy (RP).MATERIALS AND METHODS: Using a stratified cohort sampling design, we evaluated...

Cite
Brooks MA, Thomas L, Magi-Galluzzi C, et al. Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy. Urol Oncol. 2021;doi: 10.1016/j.urolonc.2021.10.005.
Brooks, M. A., Thomas, L., Magi-Galluzzi, C., Li, J., Crager, M. R., Lu, R., Baehner, F. L., Abran, J., Aboushwareb, T., & Klein, E. A. (2021). Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy. Urologic oncology, . https://doi.org/10.1016/j.urolonc.2021.10.005
Brooks, Michael A, et al. "Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy." Urologic oncology vol. (2021). doi: https://doi.org/10.1016/j.urolonc.2021.10.005
Brooks MA, Thomas L, Magi-Galluzzi C, Li J, Crager MR, Lu R, Baehner FL, Abran J, Aboushwareb T, Klein EA. Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy. Urol Oncol. 2021 Nov 22; doi: 10.1016/j.urolonc.2021.10.005. Epub 2021 Nov 22. PMID: 34824014.
Copy Download .nbib Format: NLM
Point-of-Care Ultrasound-Guided Protocol to Confirm Central Venous Catheter Placement in Pediatric Patients Undergoing Cardiothoracic Surgery: A Prospective Feasibility Study.

Journal of clinical medicine

Baehner T, Rohner M, Heinze I, Schindler E, Wittmann M, Strassberger-Nerschbach N, Kim SC, Velten M.
PMID: 34945270
J Clin Med. 2021 Dec 20;10(24). doi: 10.3390/jcm10245971.

BACKGROUND: Central venous catheters (CVC) are commonly required for pediatric congenital cardiac surgeries. The current standard for verification of CVC positioning following perioperative insertion is postsurgical radiography. However, incorrect positioning may induce serious complications, including pleural and pericardial effusion,...

Cite
Baehner T, Rohner M, Heinze I, et al. Point-of-Care Ultrasound-Guided Protocol to Confirm Central Venous Catheter Placement in Pediatric Patients Undergoing Cardiothoracic Surgery: A Prospective Feasibility Study. J Clin Med. 2021;10(24)doi: 10.3390/jcm10245971.
Baehner, T., Rohner, M., Heinze, I., Schindler, E., Wittmann, M., Strassberger-Nerschbach, N., Kim, S. C., & Velten, M. (2021). Point-of-Care Ultrasound-Guided Protocol to Confirm Central Venous Catheter Placement in Pediatric Patients Undergoing Cardiothoracic Surgery: A Prospective Feasibility Study. Journal of clinical medicine, 10(24), . https://doi.org/10.3390/jcm10245971
Baehner, Torsten, et al. "Point-of-Care Ultrasound-Guided Protocol to Confirm Central Venous Catheter Placement in Pediatric Patients Undergoing Cardiothoracic Surgery: A Prospective Feasibility Study." Journal of clinical medicine vol. 10,24 (2021). doi: https://doi.org/10.3390/jcm10245971
Baehner T, Rohner M, Heinze I, Schindler E, Wittmann M, Strassberger-Nerschbach N, Kim SC, Velten M. Point-of-Care Ultrasound-Guided Protocol to Confirm Central Venous Catheter Placement in Pediatric Patients Undergoing Cardiothoracic Surgery: A Prospective Feasibility Study. J Clin Med. 2021 Dec 20;10(24). doi: 10.3390/jcm10245971. PMID: 34945270; PMCID: PMC8706795.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18 entries